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The promise of a stem/progenitor cell-mediated cardiac repair after myocardial infarction has 
fascinated basic scientists and clinical cardiologists alike, and initial small- and intermediate 
scale clinical studies have examined the effects of a single intracoronary administration of 
unfractionated or mononuclear bone marrow cells (BMCs) on left ventricular (LV) function 
in patients after myocardial infarction.  Several recent meta-analyses of these controlled 
clinical studies have suggested a moderate, but significant improvement of LV ejection 
fraction by BMC therapy in patients after myocardial infarction (MI).1, 2  The most recent 
meta-analysis by Martin-Rendon et al. reported an improvement in LV ejection fraction of 
2.99 % in patients undergoing BMC therapy after MI.2  This was close to the observed 
improvement in LV ejection fraction of 2.5 % in the REPAIR-AMI (Remodeling in Acute 
Myocardial Infarction) trial, the largest randomised, controlled clinical study of BMC therapy 
in patients after MI.3  Although these potential effects of BMC therapy on LV function are 
less than many investigators were hoping for, it should be noted that several of our 
established clinical therapies with an impact on prognosis in patients with myocardial 
infarction and a reduced LV function, such as ACE inhibitor or beta-blocker therapy, are 
associated with similar improvements in LV ejection fraction4 and have been observed in 
patients after MI with a less optimal background therapy as compared to present studies.  
There are, however, many remaining open questions with respect to mechanisms of 
stem/progenitor cell therapy after MI and potential strategies to optimise its effects. 
 
As far as now, bone marrow-derived cells have either been used unfractionated or as 
mononuclear cells in clinical studies in patients after MI.  This clearly represents a 
heterogenous population of cells, so that it remains unclear which of the containing cells is 
particularly important for potential effects on cardiac repair.   In the present issue of the 
European Heart Journal Tendera et al. report the results of the REGENT trial (Myocardial 
Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute 
Myocardial Infarction), a multicenter study comparing the effect of unselected bone marrow 
mononuclear cells with an approximately 100-times lower number of selected CD34+/KDR+ 
bone marrow-derived mononuclear cells in patients after myocardial infarction (Figure 1).5  
The rational for selecting CD34+/KDR+ cells was based on the observation from clinical 
studies that these cells are mobilised from the bone marrow in response to myocardial 
ischemia6 and from experimental studies indicating that these cells may express endothelial 
and cardiac lineage markers.7 
 
Although 200 patients were randomized to intracoronary infusion of unselected (n=80) or 
selected (n=80) mononuclear BMCs or to the control group (n=40) without BMC therapy, the 
primary endpoint of the study was evaluated in 117 patients, i.e. in 58.5 % of the patients 
included the study.  The primary endpoint was defined as change of LV ejection fraction and 
volumes as measured by MRI before and 6 months after the procedure.  In the single analysis 
of each cell-therapy group LV ejection fraction increased significantly by approximately 3 %, 
that was not observed in the control group, however, the absolute differences between the 
groups did not reach statistical significance after Bonferroni correction.  A possible 
explanation for the lack of significance between the groups may be a reduced power of the 
study, due to the analysis of the primary endpoint in less than 60 % of the patients and a 
smaller change in LV ejection fraction after BMC therapy than expected when the study was 
planned (expected change of LV-EF >5%).   This may be supported by the observation, that 
the magnitude of the change of LV ejection fraction in the cell therapy groups corresponds 
well to what has been reported in the above meta-analyses and the largest randomised study 
in the field, the REPAIR-AMI trial.3  We have therefore to interpret the results of the 
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REGENT trial with caution, since a limited power of the study may have prevented to show a 
significant difference for the primary endpoint, as has been pointed out by the authors.  
 
Interestingly, the analysis of potential factors favouring the effect of BMC therapy on LV 
function in the REGENT trial revealed that a significant increase of LV ejection fraction was 
only observed in patients treated with BMCs who had a baseline LV ejection fraction below 
the median (i.e. LV-EF<37%).  This corresponds well to the observation in the REPAIR-
AMI study, that patients with a lower baseline LV ejection fraction derived most benefit.3  
Therefore, these analyses are hypothesis-generating that selecting patients with a severe 
impairment of LV ejection fraction after myocardial infarction may be one way to increase 
the benefit of this therapy.  
The study design of Tendera et al. did not compare similar numbers of unselected and 
selected BMCs (the number of selected BMCs was approximately 100-times lower), and the 
“selected” cells remained contained in the unselected BMCs.5  Such a selection of 
subfractions of BMCs would  be expected to augment the effect of cell therapy on cardiac 
function only when there are other cell fractions within BMCs that would exert an inhibitory 
effect on cardiac repair, that remains largely unkown at present.  However, a similar increase 
of LV-EF with unselected cells and selected cells of a substantially lower number would 
argue for an important role of the selected cell population for the effects on cardiac function.  
 
The mechanisms whereby bone marrow-derived cell therapy may improve cardiac function 
are still debated and not entirely clear.  Whereas initial experimental studies had suggested a 
rapid transdifferentiation of bone-marrow-derived stem cells (c-kit+, lineage-) into 
cardiomyocytes after cardiac injection post-myocardial infarction8, likely inspired by the 
concept of a high stem cell plasticity of adult stem cells, later experimental studies using 
genetic techniques to follow bone marrow cell fate reported that transdifferentiation of bone-
marrow-derived stem cells into cardiomyocytes did not explain the observed effects of bone 
marrow-derived stem cells on LV function,9 and suggested that BMCs rather act by paracrine 
mechanisms to improve cardiac function, such as by stimulation of capillary growth, 
prevention of cardiomyocyte apoptosis or stimulation of resident cardiac stem cells.10, 11  In 
fact, inhibition of endogenous mobilisation of bone-marrow-derived stem cells after 
experimental myocardial infarction augmented myocardial damage after MI and resulted in  
an impaired capillary growth in the infarct border zone.11  The debate of the concept of stem 
cell plasticity, i.e. whether adult stem cells in addition to pluripotent stem cells can 
transdifferentiate into non-organ specific cell types, is not unique to the cardiovascular field.  
Similarly, several groups had observed that adult bone marrow-derived stem cells repaired 
damaged liver tissue, that was initially suggested to result from transdifferentiation into liver 
cells,  but later was reported to be a consequence of cell fusion with liver cells.12  Cell fusion 
has also been suggested to explain in part the discrepant findings with respect to the 
transdifferentiation potential of BMC into cardiomyocytes.13 Whether strategies to enhance 
cardiomyogenic differentiation of adult stem/progenitor cells, i.e. by activation of cardiogenic 
Wnt pathways14 or by small molecules15 or whether induction of pluripotency16 will be 
required to efficiently enhance cardiomyogenesis remains one of the important future 
challenges.  
 
While the initially perceived rapid chance for a complete cardiac repair by stem/progenitor 
cell therapy after MI has generated high expectations, now the potential of this therapy needs 
to be carefully developed by addressing important remaining questions, including the optimal 
cell types and preconditioning, the timing and dosing of cells to be used, how to augment the 
functional repair capacity of transplanted cells and how to optimise their homing and 
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engraftment in the heart and how to select the patients that may benefit most from this 
therapy.  An important focus of present basic and clinical studies is therefore directed 
towards optimising the outcome and effect of stem/progenitor cell-based therapies, such as by 
improving stem/progenitor cell repair capacity and the process of cardiac cell homing.  
Notably, vascular and pro-angiogenic repair capacity of autologous stem/progenitor cells is 
reduced by cardiovascular risk factors, such as diabetes17 and by aging, likely representing an 
important potential target for optimisation of cell-based therapy.  A reduced nitric oxide (NO) 
production by both, circulating and bone-marrow-derived stem/progenitor cells has been 
suggested to be critical for their reduced in vivo repair capacity.17, 18  Augmented expression 
of endothelial NO-synthase by gene transfer into endothelial progenitor cells prior to cardiac 
transplantation is currently explored in the clinical ENACT-AMI trial as a strategy to 
augment cell repair capacity.  Furthermore, several strategies are examined to improve 
homing and engraftment of mobilised stem/progenitor cells,19 i.e. the SITAGRAMI trial.  
Moreover, the timing and dosing of cell transplantation may be relevant for the effect of 
BMC therapy after MI, that is currently examined in the SWISS-AMI and BOOST-2 trials.   
 
Whereas the present clinical studies of BMC therapy have largely examined the effect on LV 
ejection fraction, i.e. a surrogate endpoint, ultimately, the validation of cardiac cell therapy 
for clinical use will depend on the demonstration of a benefit with regard to clinical 
outcomes, similar as with reperfusion therapy.  In this respect, besides optimising the 
conditions of cell therapy, selection of the patients who may benefit most from this therapy, 
i.e. based on LV ejection fraction and other parameters, will likely be an important issue to 
adaequately examine the clinical potential of this novel therapeutic concept. 
 
 
 
 
Figure legend  
The REGENT trial examined the effect of a single intracoronary administration of either 
unselected or CD34+/CXCR4+ selected bone-marrow-derived mononuclear cells on the 
change of LV ejection fraction and volumes after myocardial  infarction (as compared to a 
control group without BMC therapy).  The number of selected BM cells was approximately 
100-times lower as compared to unselected BM cells.  This is the first clinical study aiming 
to examine which cells contained in bone marrow are particularly important for potential 
effects on cardiac repair after MI.   
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